Sartorius Ag · XETR:SRT
Sartorius — FY 2025 Earnings Presentation
19 slides from Sartorius's earnings presentation, Feb 3, 2026
Slide 1: Investor Conference Call Preliminary FY 2025 Results | 2026 Outlook
Investor Conference Call Preliminary FY 2025 Results | 2026 Outlook Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | February 3, 2026
Slide 2: Agenda
Agenda Sartorius Group FY2025 results | FY 2026 outlook Sartorius Stedim Biotech Group FY 2025 results | FY 2026 outlook Questions & Answers 2
Slide 3: Delivered on 2025 guidance
Sartorius Group Delivered on 2025 guidance 2025 Guidance Initial (quant.) guidance Updated guidance FY 2025 (prelim.) Sales revenue growth +~6 (+/- approx. 2 pp) +~7 +7.6 (in %, cc)1 Ul EBITDA margin Slightly above (in %) ~29 to ~30 29.7 29.5 Capex (in %) ~12.5 ~12.5 12.5 Net debt | ul EBITDA(x) app
Slide 4: 2025 characterized by strong performance; confident 2026 outlook
Sartorius Group 2025 characterized by strong performance; confident 2026 outlook Group: ▪ Clear profitable revenue growth driven by strong consumables business in both divisions ▪ Substantial margin expansion driven by scale effects, favorable product mix; FX/US-tariffs dilutive ▪ Healthy cashflow;
Slide 5: Progress on key steps to enable our future growth
Sartorius Group Progress on key steps to enable our future growth Select product launches Sartopore Evo® Sartocon® Pionic® Incucyte® Octet® iQUE® Cassette Spin & Dual CX3 R8e 5 VYBR Acquisitions & Partnerships Major capex projects Aubagne Göttingen Freiburg Songdo 5
Slide 6: Robust growth fueled by consumables demand
Sartorius Group Robust growth fueled by consumables demand Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.6% cc | +4.7% +9.5% cc | +6.5% +0.2% cc | -2.5% 3,381 3,538 2,690 2,865 691 673 FY 2024
Slide 7: All regions contributed to positive business development
Sartorius Group All regions contributed to positive business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +5.8% cc +8.9% cc +8.9% cc 1,389 1,467 1,200 1,251 792 820 FY 2024 FY 2025 FY 2024 FY 2025 FY 2024 FY 2025 ▪
Slide 8: Improving profitability driven by volume, mix and scale effects
Sartorius Group Improving profitability driven by volume, mix and scale effects Sartorius Group Bioprocess Solutions Lab Products & Services Ul. EBITDA & margin | Ul. EBITDA & margin | Ul. EBITDA & margin | € in millions € in millions € in millions +11.2% +15.2% 29.7% 31.7% 28.0% 29.3% -8.6% 1,052 9
Slide 9: Strong profit performance; good cash generation; capex in line with plan
Sartorius Group Strong profit performance; good cash generation; capex in line with plan Sartorius Group FY 2024 FY 2025 in % in millions of € Underlying net profit1,2 280 331 +18.2 ▪ Overproportionate increase in net result and underlying EPS Underlying EPS (ord.) 4.05 4.78 +18.1 ▪ Operating cash f
Slide 10: Deleveraging progressing well; reiterating commitment to investment-grade rating
Sartorius Group Deleveraging progressing well; reiterating commitment to investment- grade rating Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Dec. 31, 5,000 in millions of € unless otherwise specified 2024 2025 5.0 4,000 4.0 Equity ratio in % 38.6
Slide 11: Confident outlook 2026
Sartorius Group Confident outlook 2026 Guidance 2026 Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue growth1 ~5% to ~9% ~6% to ~10% ~2% to ~6% Underlying EBITDA margin Slightly above 30% Slightly above 32% Slightly below 21% ▪ Group sales growth includes ~1pp contribution
Slide 12: Agenda
Agenda Sartorius Group FY2025 results | FY 2026 outlook Sartorius Stedim Biotech Group FY 2025 results | FY 2026 outlook Questions & Answers 12
Slide 13: Delivered on 2025 guidance
Sartorius Stedim Biotech Group Delivered on 2025 guidance 2025 Guidance Initial (quant.) guidance Updated guidance FY 2025 (prelim.) Sales revenue growth + ~7 (+/- approx. 2 pp) +~9 +9.6 (in %, cc)1 Ul EBITDA margin (in %) ~30 to ~31 ~31 30.8 Capex (in %) ~13.0 ~13.0 13.3 Net debt | ul EBITDA(x) app
Slide 14: Strong profitable growth driven by consumables demand
Sartorius Stedim Biotech Group Strong profitable growth driven by consumables demand Sales revenue | € in millions Ul. EBITDA & margin | € in millions +9.6% cc | +6.7% +17.3% 2,967 2,780 30.8% 28.0% 914 779 FY 2024 FY 2025 FY 2024 FY 2025 ▪ LTM BtB ratio consistently >1 ▪ Double-digit sales growth i
Slide 15: All regions contributed to positive business development
Sartorius Stedim Biotech Group All regions contributed to positive business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.3% cc +11.8% cc +10.7% cc 1,241 1,159 982 1,053 639 673 FY 2024 FY 2025 FY 2024 FY 2025 FY
Slide 16: Strong profit performance; good cash generation; capex in line with plan
Sartorius Stedim Biotech Group Strong profit performance; good cash generation; capex in line with plan Sartorius Stedim Biotech FY 2024 FY 2025 in % in millions of € Underlying net profit1,2 338 428 +26.7 ▪ Overproportionate increase in net result and underlying EPS Underlying EPS3 3.49 4.40 +26.0
Slide 17: Strong balance sheet; deleveraging well on track
Sartorius Stedim Biotech Group Strong balance sheet; deleveraging well on track Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Dec. 31, 5.0 in millions of € unless otherwise specified 2024 2025 3,000 4.0 Equity ratio in % 48.7 51.7 2,0
Slide 18: Confident outlook 2026
Sartorius Stedim Biotech Group Confident outlook 2026 Guidance 2026 Sales revenue growth1 Underlying EBITDA margin Sartorius Stedim Biotech Group ~6% to ~10% Slightly above 31% ▪ Sales growth includes ~1pp contribution from US tariff-related surcharges For financial modelling on SSB level ▪ Capex ra
Slide 19: Questions & Answers
19 Questions & Answers SARTORI